clinical trial · NCT04856917
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Acne VulgarisImsidolimabPlacebo
brief summary
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
started
May 15, 2021
primary completion
Feb 1, 2022
completion
Mar 29, 2022
last updated
Sep 22, 2025
detailed description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adolescent and adult participants with acne vulgaris (AV). This study also will characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with AV.
official title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol